Search

Roche Holding AG

Abrir

SetorSaúde

295 -1.99

Visão Geral

Variação de preço das ações

24h

Atual

Mín

291

Máximo

302.2

Indicadores-chave

By Trading Economics

Rendimento

6.3B

Vendas

31B

P/E

Médio do Setor

29.748

63.778

Rendimento de Dividendos

3.1

Margem de lucro

20.347

Funcionários

103,249

EBITDA

11B

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.10%

2.39%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

233B

Abertura anterior

296.99

Fecho anterior

295

Sentimento de Notícias

By Acuity

48%

52%

176 / 386 Ranking em Healthcare

Roche Holding AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de mar. de 2025, 09:23 UTC

Grandes Movimentos do Mercado

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

30 de jan. de 2025, 09:36 UTC

Ganhos

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

30 de jan. de 2025, 06:32 UTC

Ganhos

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

26 de nov. de 2024, 15:27 UTC

Aquisições, Fusões, Aquisições de Empresas

Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion

31 de mar. de 2025, 09:31 UTC

Ações em Alta

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

13 de mar. de 2025, 07:46 UTC

Conversa de Mercado

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

12 de mar. de 2025, 16:34 UTC

Principais Notícias

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 de mar. de 2025, 08:51 UTC

Conversa de Mercado

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

12 de mar. de 2025, 08:18 UTC

Conversa de Mercado

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

13 de fev. de 2025, 11:43 UTC

Conversa de Mercado

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

30 de jan. de 2025, 07:56 UTC

Conversa de Mercado
Ganhos

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

30 de jan. de 2025, 06:04 UTC

Ganhos

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

30 de jan. de 2025, 06:04 UTC

Ganhos

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

30 de jan. de 2025, 06:04 UTC

Ganhos

Roche Issues 2025 View

30 de jan. de 2025, 06:03 UTC

Ganhos

Roche Raises Dividend to CHF9.70 Vs CHF9.60

30 de jan. de 2025, 06:03 UTC

Ganhos

Roche 2024 Core Operating Profit CHF20.82B

30 de jan. de 2025, 06:03 UTC

Ganhos

Roche 2024 Net Pft CHF9.19B

30 de jan. de 2025, 06:02 UTC

Ganhos

Analysts Saw 2024 Core EPS at CHF18.59

30 de jan. de 2025, 06:02 UTC

Ganhos

Roche 2024 Core EPS CHF18.80

30 de jan. de 2025, 06:02 UTC

Ganhos

Roche 2024 Sales EUR60.50B

30 de jan. de 2025, 06:02 UTC

Ganhos

Analysts Saw Roche 2024 Revenue at CHF60.41B

30 de jan. de 2025, 06:01 UTC

Ganhos

Roche 2024 Sales CHFB

28 de jan. de 2025, 10:30 UTC

Principais Notícias

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

28 de jan. de 2025, 07:24 UTC

Conversa de Mercado

Roche's Breast Cancer Drug Extends Life of Patients -- Market Talk

15 de jan. de 2025, 10:22 UTC

Conversa de Mercado

Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk

8 de jan. de 2025, 06:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Roche: 66.11% of Poseida's Shares Were Validly Tendered in Offer

8 de jan. de 2025, 06:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Roche Intends to Complete Acquisition of Poseida Therapeutics Later Wednesday

16 de dez. de 2024, 22:03 UTC

Principais Notícias

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13 de dez. de 2024, 16:36 UTC

Conversa de Mercado

Swiss Equities an Overweight Pick Next Year -- Market Talk

26 de nov. de 2024, 16:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Why This Gene-Therapy Company's Stock Is Rising 228% -- Barrons.com

Roche Holding AG Previsão

Sentimento

By Acuity

176 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.